Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

Synlogic Presents at Global PKU Patient Meeting

Synlogic Reports Second Quarter Financial Results and Provides Business Update

Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference

Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU)

Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)

Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease

Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting

Synlogic Reminds Stockholders of 2021 Annual General Meeting Details

Synlogic to Present at Upcoming Virtual Banking and Industry Conference

Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Disease